drugset / Trial / NCT02763319
A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of the study is to compare the safety and efficacy of Tafasitamab with BEN versus RTX with BEN in adult patients with relapsed of refractory DLBCL.
Timeline
- Start
- 2016-11-28
- Primary completion
- 2024-06-21
- Completion
- 2024-06-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Subject | Tafasitamab | Monoclonal antibody | 12 mg/kg | Intravenous |
| Background | Bendamustine | Small molecule | — | — |